Tekmira Pharmaceuticals said this week that it has begun enrolling patients in a phase I trial of its Ebola virus infection treatment TKM-Ebola.
The 56-patient, placebo-controlled study has two arms. The first will test single ascending doses of the siRNA-based drug in up to six cohorts of four patients each. The second arm will examine multiple ascending doses in three four-patient cohorts.
TKM-Ebola is being developed with the support of a $140 million contract from the US government. In 2010, Tekmira showed that a cocktail of modified siRNAs targeting the Zaire Ebola virus L polymerase, viral protein 24, and viral protein 35 could completely protect non-human primates from a lethal dose of the virus when delivered using proprietary lipid nanoparticles (GSN 8/9/2010).